Dr. Matthew T. Hoffmann, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 821
Licensed in Texas since 2017, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
TX license R2875 (first issued 2017; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Oliver Street 5.01(a) Inc (168 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 821
- Services billed
- 4,686
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,910 | 316 |
| Established patient office or other outpatient visit, 20-29 minutes | 780 | 538 |
| Destruction of precancer skin growth, 1 growth | 512 | 385 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 383 | 323 |
| Destruction of skin growth, 1-14 growths | 206 | 176 |
| Biopsy of related skin growth, first growth | 182 | 168 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 139 | 105 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 105 | 99 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | 88 | 82 |
| Established patient office or other outpatient visit, 10-19 minutes | 81 | 75 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 112 payments worth $3,137 in total to this clinician.
| Kerecis Limited | $1,232 |
|---|---|
| AbbVie Inc. | $383 |
| Janssen Biotech, Inc. | $307 |
| Genzyme Corporation | $284 |
| Regeneron Healthcare Solutions, Inc. | $193 |
| Lilly USA, LLC | $114 |
| UCB, Inc. | $96.25 |
| Organon LLC | $93.63 |
| Food and Beverage | $3,127 |
|---|---|
| Education | $9.65 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Feb 25, 2025 | Education SKYRIZI · IMMUNOLOGY · in-kind | $9.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $6,745 in research payments for these studies, mostly to the institutions running them.
- M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
AbbVie Inc. - Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
Sanofi US Services Inc. · Completed · NCT05991323 - A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.